Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional) | PAR 21 100

Frequently Asked Questions (FAQs)

What is the title and funding opportunity number for this NIH grant?

The opportunity is titled "Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional)" and the Funding Opportunity Number is PAR-21-100.

What is the main purpose of this funding opportunity?

The purpose is twofold: (1) to improve scientific understanding of how music affects the brain when used in therapeutic contexts, and (2) to use that mechanistic knowledge to design, refine, and improve evidence-based music interventions that can enhance health outcomes or help prevent, manage, or treat diseases and disorders.

How does NIH define the overall direction of "music medicine" in this opportunity?

This opportunity supports treating music as a therapeutic tool that can be studied, measured, and refined like other health interventions. NIH emphasizes approaches that are testable, reproducible, and scalable, with clear reasoning about why specific musical features, delivery methods, dosage, or engagement strategies should lead to a particular therapeutic effect.

What grant mechanism is used?

The mechanism is an NIH R01 research project grant.

Are clinical trials required?

No. Clinical trials are optional under this funding opportunity. Applicants may propose basic, translational, or early-stage clinical work depending on the scientific goals.

What kinds of research topics are responsive to this FOA?

Responsive projects can include research on how the brain processes music, how musical experiences modify brain function or structure, and how those changes relate to health-relevant outcomes. Studies may also connect music-related neural activity to broader physiological systems, as long as the work is grounded in rigorous scientific approaches.

What physiological or behavioral systems can be studied in connection with music?

The FOA gives examples such as stress biology, autonomic function, immune or endocrine responses, pain modulation, motor control, cognition, mood regulation, and social and communication processes, among others.

Does this opportunity support research across the lifespan?

Yes. The FOA welcomes studies across the lifespan, including childhood development and learning, adult functioning, and aging, with attention to how music influences specific biological functions.

Does NIH support intervention development or only mechanistic studies?

Both are supported. In addition to mechanistic studies, the FOA allows preliminary or early-stage interventions that can serve as a foundation for future therapeutic trials.

What types of early-stage or preliminary intervention work are mentioned?

Examples include feasibility testing, optimizing intervention parameters, identifying biomarkers or neural signatures of response, and determining the most appropriate outcome measures for later-stage clinical studies.

What does NIH mean by grounding projects in "rigorous scientific approaches"?

Based on the description provided, NIH is looking for research that goes beyond descriptive accounts and instead uses measurable, testable methods to explain how and why music produces health-relevant effects and how interventions can be systematically designed and evaluated.

Is collaboration encouraged?

Yes. The FOA places notable emphasis on collaboration, especially when it increases scientific rigor and real-world relevance.

What kinds of collaborators or disciplines does NIH encourage teams to include?

NIH encourages teams that may include basic neuroscientists, behavioral scientists, technology developers (such as digital platforms, sensors, or adaptive music systems), music intervention experts (including music therapists and clinicians who deliver structured music-based care), and disease-specific clinical researchers.

Can technology-enabled music interventions be part of the proposal?

Yes. The FOA explicitly mentions technology developers and examples such as digital platforms, sensors, and adaptive music systems as potential collaborators, indicating that technology-enabled approaches can be relevant when they strengthen the proposed science and intervention strategy.

Who is eligible to apply?

Eligibility is broad and includes many U.S.-based organizations, such as state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing or Indian housing authorities; Native American tribal organizations that are not federally recognized; nonprofits with or without 501(c)(3) status (as described in the listing); for-profit organizations (other than small businesses); small businesses; and other eligible entities.

Are minority-serving institutions and community organizations eligible?

Yes. The FOA explicitly highlights additional eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving Institutions, HBCUs, TCCUs, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.

Can a non-U.S. (foreign) institution apply as the main applicant?

No. Foreign institutions (non-U.S. entities) are not eligible to apply as the applicant organization for this opportunity.

Are foreign components allowed at all?

Yes. The FOA notes that foreign components are allowed under NIH policy, and non-domestic components of U.S. organizations may participate when justified.

Which agency runs this program?

This is a discretionary grant program administered by the National Institutes of Health (NIH).

Is this opportunity associated with multiple NIH program areas?

Yes. The listing includes multiple CFDA numbers, indicating the topic is cross-cutting and relevant to multiple NIH institutes and centers.

What CFDA numbers are associated with this opportunity?

The CFDA numbers listed are 93.121, 93.213, 93.242, 93.273, 93.279, 93.307, 93.361, 93.393, 93.853, 93.866, and 93.867.

When was this opportunity originally posted?

The original posting date listed is December 23, 2020.

What is the closing date shown in the provided listing?

The original closing date provided in the source is February 5, 2023.

Does the listing provide an award ceiling or expected number of awards?

No. The provided fields do not specify an award ceiling or an expected number of awards.

How should applicants think about budgets if no award ceiling is listed?

Because an award ceiling is not specified in the provided information, applicants are typically expected to consult the full FOA along with NIH standard R01 budget guidance and institute-specific paylines or funding priorities when planning the project budget and scope.

What kinds of outcomes is NIH aiming to improve through funded research?

The FOA is aimed at advancing evidence-based uses of music that can enhance health outcomes or help prevent, manage, or treat specific diseases and disorders, supported by stronger mechanistic understanding of how music affects the brain and body.

What distinguishes "descriptive" work from the kind of work NIH is encouraging here?

Based on the description provided, NIH is pushing the field toward studies and interventions that are measurable and testable, where investigators can explain why specific musical or contextual elements should drive the intended therapeutic effects, rather than only describing associations or experiences.

Can projects focus on identifying biomarkers or neural signatures related to music interventions?

Yes. The FOA explicitly mentions identifying biomarkers or neural signatures of response as an example of early-stage work that can support later clinical studies.

Can projects focus on selecting or validating outcome measures for future trials?

Yes. Determining the most appropriate outcome measures for later-stage clinical studies is specifically mentioned as an allowable type of preliminary work.

Can proposals address both neuroscience mechanisms and real-world delivery?

Yes. The FOA emphasizes mechanistic understanding while also encouraging collaboration and intervention development that improves real-world relevance, including considerations such as delivery method, dosage, and engagement strategies.